Sphingolipids in genetic and acquired forms of chronic kidney diseases

Current Medicinal Chemistry

Volumn 24, Issue 12, 2017, Pages 1238-1275

  Ueda, Norishi ^a  

^a Public Central Hospital of Matto Ishikawa   (Japan)

Author keywords

Apoptosis; Bcl 2 family proteins; Ceramide; Glomerular injury; Mitochondria; Reactive oxygen species; Renin angiotensin aldosterone system; Sphingosine 1 phosphate

Indexed keywords

CERAMIDE; PROTEIN BCL 2; SPHINGOLIPID; SPHINGOSINE 1 PHOSPHATE;

APOPTOSIS; CHRONIC KIDNEY FAILURE; CONGENITAL NEPHROTIC SYNDROME; DISEASE COURSE; GLOMERULONEPHRITIS; GLOMERULUS; HEMOLYTIC UREMIC SYNDROME; HIV ASSOCIATED NEPHROPATHY; HUMAN; KIDNEY FIBROSIS; KIDNEY POLYCYSTIC DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MITOCHONDRIAL PERMEABILITY; OUTER MEMBRANE; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; GENETICS; METABOLISM; RENAL INSUFFICIENCY, CHRONIC;

ANIMALS; HUMANS; RENAL INSUFFICIENCY, CHRONIC; SPHINGOLIPIDS;

EID: 85021098947     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867324666170112114525     Document Type: Review

References (337)

1. Ueda, N. Ceramide-induced apoptosis in renal tubular cells: a role of mitochondria and sphingosine-1-phoshate. Int. J. Mol. Sci., 2015, 16(3), 5076-5124.
2. Xu, Y.H.; Barnes, S.; Sun, Y.; Grabowski, G.A. Multisystem disorders of glycosphingolipid and ganglioside metabolism. J. Lipid Res., 2010, 51(7), 1643-1675.
3. Ishibashi, Y.; Kohyama-Koganeya, A.; Hirabayashi, Y. New insights on glucosylated lipids: metabolism and functions. Biochim. Biophys. Acta., 2013, 1831, 1475-1485.
4. Young, M.M.; Kester, M.; Wang, H.G. Sphingolipids: regulators of crosstalk between apoptosis and autophagy. J. Lipid Res., 2013, 54(1), 5-19.
5. Garcia-Ruiz, C.; Morales, A.; Fernández-Checa, J.C. Glycosphingolipids and cell death: one aim, many ways. Apoptosis, 2015, 20(5), 607-620.
6. Takabe, K.; Paugh, S.W.; Milstien, S.; Spiegel, S. Insideout signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol. Rev., 2008, 60(2), 181-195.
7. Van Brocklyn, J.R.; Williams, J.B. The control of the balance between ceramide and sphingosine-1-phosphate by sphingosine kinase: oxidative stress and the seesaw of cell survival and death. Comp. Biochem. Physiol. B Biochem. Mol. Biol., 2012, 163(1), 26-36.
8. Marshall, J.; Ashe, K.M.; Bangari, D.; McEachern, K.; Chuang, W.L.; Pacheco, J.; Copeland, D.P.; Desnick, R.J.; Shayman, J.A.; Scheule, R.K.; Cheng, S.H. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. PLoS One, 2010, 5(11), e15033.
9. Schulze, H.; Sandhoff, K. Lysosomal lipid storage diseases. Cold Spring Harb. Perspect. Biol., 2011, 3(6), a004804.
10. Tøndel, C.; Bostad, L.; Larsen, K.K.; Hirth, A.; Vikse, B.E.; Houge, G.; Svarstad, E. Agalsidase benefits renal histology in young patients with Fabry disease. J. Am. Soc. Nephrol., 2013, 24(1), 137-148.
11. Waldek, S.; Feriozzi, S. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy? BMC Nephrol., 2014, 15, 72.
12. Chatterjee, S.; Shi, W.Y.; Wilson, P.; Mazumdar, A. Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease. J. Lipid Res., 1996, 37(6), 1334-1344.
13. Natoli, T.A.; Smith, L.A.; Rogers, K.A.; Wang, B.; Komarnitsky, S.; Budman, Y.; Belenky, A.; Bukanov, N.O.; Dackowski, W.R.; Husson, H.; Russo, R.J.; Shayman, J.A.; Ledbetter, S.R.; Leonard, J.P.; Ibraghimov-Beskrovnaya, O. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat. Med., 2010, 16(7), 788-792.
14. Natoli, T.A.; Husson, H.; Rogers, K.A.; Smith, L.A.; Wang, B.; Budman, Y.; Bukanov, N.O.; Ledbetter, S.R.; Klinger, K.W.; Leonard, J.P.; Ibraghimov-Beskrovnaya, O. Loss of GM3 synthase gene, but not sphingosine kinase 1, is protective against murine nephronophthisis-related polycystic kidney disease. Hum. Mol. Genet., 2012, 21(15), 3397-3407.
15. Stettner, P.; Bourgeois, S.; Marsching, C.; Traykova-Brauch, M.; Porubsky, S.; Nordström, V.; Hopf, C.; Koesters, R.; Sandhoff, R.; Wiegandt, H.; Wagner, C.A.; Gröne, H.J.; Jennemann, R. Sulfatides are required for renal adaptation to chronic metabolic acidosis. Proc. Natl. Acad. Sci. USA, 2013, 110(24), 9998-10003.
16. Haltia, A.; Solin, M.L.; Jalanko, H.; Holmberg, C.; Miettinen, A.; Holthöfer, H. Sphingolipid activator proteins in a human hereditary renal disease with deposition of disialogangliosides. Histochem. J., 1996, 28(10), 681-687.
17. Simons, M.; Schwarz, K.; Kriz, W.; Miettinen, A.; Reiser, J.; Mundel, P.; Holthöfer, H. Involvement of lipid rafts in nephrin phosphorylation and organization of the glomerular slit diaphragm. Am. J. Pathol., 2001, 159(3), 1069-1077.
18. Merscher, S.; Fornoni, A. Podocyte pathology and nephropathy - sphingolipids in glomerular diseases. Front. Endocrinol. (Lausanne), 2014, 5, 127.
19. Pereira, R.L.; Reis, V.O.; Semedo, P.; Buscariollo, B.N.; Donizetti-Oliveira, C.; Cenedeze, M.A.; Soares, M.F.; Pacheco-Silva, A.; Savage, P.B.; Câmara, N.O.; Keller, A.C. Invariant natural killer T cell agonist modulates experimental focal and segmental glomerulosclerosis. PLoS One, 2012, 7(3), e32454.
20. Yang, J.Q.; Kim, P.J.; Singh, R.R. Brief treatment with iNKT cell ligand α-galactosylceramide confers a long-term protection against lupus. J. Clin. Immunol., 2012, 32(1), 106-113.
21. Fornoni, A.; Merscher, S.; Kopp, J.B. Lipid biology of the podocytenew perspectives offer new opportunities. Nat. Rev. Nephrol., 2014, 10(7), 379-388.
22. McDonald, G.; Deepak, S.; Miguel, L.; Hall, C.J.; Isenberg, D.A.; Magee, A.I.; Butters, T.; Jury, E.C. Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients. J. Clin. Invest., 2014, 124(2), 712-724.
23. Mitsnefes, M.; Scherer, P.E.; Friedman, L.A.; Gordillo, R.; Furth, S.; Warady, B.A. Ceramides and cardiac function in children with chronic kidney disease. Pediatr. Nephrol., 2014, 29(3), 415-422.
24. Miyata, M.; Ichihara, M.; Tajima, O.; Sobue, S.; Kambe, M.; Sugiura, K.; Furukawa, K.; Furukawa, K. UVBirradiated keratinocytes induce melanoma-associated ganglioside GD3 synthase gene in melanocytes via secretion of tumor necrosis factor α and interleukin 6. Biochem. Biophys. Res. Commun., 2014, 445(2), 504-510.
25. Schwalm, S.; Pfeilschifter, J.; Huwiler, A. Targeting the sphingosine kinase/sphingosine 1-phosphate pathway to treat chronic inflammatory kidney diseases. Basic Clin. Pharmacol. Toxicol., 2014, 114(1), 44-49.
26. Nowling, T.K.; Mather, A.R.; Thiyagarajan, T.; Hernáandez-Corbacho, M.J.; Powers, T.W.; Jones, E.E.; Snider, A.J.; Oates, J.C.; Drake, R.R.; Siskind, L.J. Renal glycosphingolipid metabolism is dysfunctional in lupus nephritis. J. Am. Soc. Nephrol., 2015, 26(6), 1402-1413.
27. Che, R.; Yuan, Y.; Huang, S.; Zhang, A. Mitochondrial dysfunction in the pathophysiology of renal diseases. Am. J. Physiol. Renal Physiol., 2014, 306(4), F367-F378.
28. Spijkers, L.J.; Janssen, B.J.; Nelissen, J.; Meens, M.J.; Wijesinghe, D.; Chalfant, C.E.; De Mey, J.G.; Alewijnse, A.E.; Peters, S.L. Antihypertensive treatment differentially affects vascular sphingolipid biology in spontaneously hypertensive rats. PLoS One, 2011, 6(12), e29222.
29. Lehtonen, J.Y.; Horiuchi, M.; Daviet, L.; Akishita, M.; Dzau, V.J. Activation of the de novo biosynthesis of sphingolipids mediates angiotensin II type 2 receptor-induced apoptosis. J. Biol. Chem., 1999, 274(24), 16901-16906.
30. Bautista-Pérez, R.; del Valle-Mondragón, L.; Cano-Marténez, A.; Pérez-Méndez, O.; Escalante, B.; Franco, M. Involvement of neutral sphingomyelinase in the angiotensin II signaling pathway. Am. J. Physiol. Renal Physiol., 2015, 308(10), F1178-F1187.
31. Zhang, Y.; Pan, Y.; Bian, Z.; Chen, P.; Zhu, S.; Gu, H.; Guo, L.; Hu, C. Ceramide production mediates aldosteroneinduced human umbilical vein endothelial cell (HUVEC) damages. PLoS One, 2016, 11(1), e0146944.
32. Kitatani, K.; Akiba, S.; Sato, T. Ceramide-induced enhancement of secretory phospholipase A2 expression via generation of reactive oxygen species in tumor necrosis factor- α-stimulated mesangial cells. Cell. Signal., 2004, 16(8), 967-974.
33. Yu, R.K.; Nakatani, Y.; Yanagisawa, M. The role of glycosphingolipid metabolism in the developing brain. J. Lipid Res., 2009, 50(Suppl.), S440-S445.
34. Merrill, A.H., Jr Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem. Rev., 2011, 111(10), 6387-6422.
35. DAngelo, G.; Capasso, S.; Sticco, L.; Russo, D. Glycosphingolipids: synthesis and functions. FEBS J., 2013, 280(24), 6338-6353.
36. Giussani, P.; Tringali, C.; Riboni, L.; Viani, P.; Venerando, B. Sphingolipids: key regulators of apoptosis and pivotal players in cancer drug resistance. Int. J. Mol. Sci., 2014, 15(3), 4356-4392.
37. Won, J.S.; Singh, A.K.; Singh, I. Lactosylceramide: a lipid second messenger in neuroinflammatory disease. J. Neurochem., 2007, 103(Suppl. 1), 180-191.
38. Germain, D.P. Fabry disease. Orphanet J. Rare Dis., 2010, 5, 30.
39. Wijburg, F.A.; Bénichou, B.; Bichet, D.G.; Clarke, L.A.; Dostalova, G.; Fainboim, A.; Fellgiebel, A.; Forcelini, C.; An Haack, K.; Hopkin, R.J.; Mauer, M.; Najafian, B.; Scott, C.R.; Shankar, S.P.; Thurberg, B.L.; Tøndel, C.; Tylki-Szymańska, A.; Ramaswami, U. Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial. PLoS One, 2015, 10(5), e0124987.
40. Najafian, B.; Svarstad, E.; Bostad, L.; Gubler, M.C.; Tøndel, C.; Whitley, C.; Mauer, M. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int., 2011, 79(6), 663-670.
41. Ortiz, A.; Cianciaruso, B.; Cizmarik, M.; Germain, D.P.; Mignani, R.; Oliveira, J.P.; Villalobos, J.; Vujkovac, B.; Waldek, S.; Wanner, C.; Warnock, D.G. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol. Dial. Transplant., 2010, 25(3), 769-775.
42. Bley, A.E.; Giannikopoulos, O.A.; Hayden, D.; Kubilus, K.; Tifft, C.J.; Eichler, F.S. Natural history of infantile G(M2) gangliosidosis. Pediatrics, 2011, 128(5), e1233-e1241.
43. Lew, R.M.; Burnett, L.; Proos, A.L.; Delatycki, M.B. Tay-Sachs disease: current perspectives from Australia. Appl. Clin. Genet., 2015, 8, 19-25.
44. Taketomi, T.; Kawamura, N. Cerebral and visceral glycolipids in a case of Tay-Sachs disease. J. Biochem., 1969, 66(2), 165-174.
45. Itoh, H.; Tanaka, J.; Morihana, Y.; Tamaki, T. The fine structure of cytoplasmic inclusions in brain and other visceral organs in Sandhoff disease. Brain Dev., 1984, 6(5), 467-474.
46. Sandhoff, K.; Andreae, U.; Jatzkewitz, H. Deficient hexozaminidase activity in an exceptional case of Tay-Sachs disease with additional storage of kidney globoside in visceral organs. Life Sci., 1968, 7(6), 283-288.
47. Takahashi, A.; Saito, K.; Koizumi, Y. An autopsy case of Sandhoffs disease. Beitr. Pathol., 1974, 152(4), 418-428.
48. Tatematsu, M.; Imaida, K.; Ito, N.; Togari, H.; Suzuki, Y.; Ogiu, T. Sandhoff disease. Acta Pathol. Jpn., 1981, 31(3), 503-512.
49. Grabowski, G.A. Gaucher disease and other storage disorders. Hematology Am. Soc. Hematol. Educ. Program, 2012, 2012, 13-18.
50. Dandana, A.; Ben Khelifa, S.; Chahed, H.; Miled, A.; Ferchichi, S. Gaucher disease: Clinical, biological and therapeutic aspects. Pathobiology, 2016, 83(1), 13-23.
51. Becker-Cohen, R.; Elstein, D.; Abrahamov, A.; Algur, N.; Rudensky, B.; Hadas-Halpern, I.; Zimran, A.; Frishberg, Y. A comprehensive assessment of renal function in patients with Gaucher disease. Am. J. Kidney Dis., 2005, 46(5), 837-844.
52. Santoro, D.; Rosenbloom, B.E.; Cohen, A.H. Gaucher disease with nephrotic syndrome: response to enzyme replacement therapy. Am. J. Kidney Dis., 2002, 40(1), E4.
53. Smith, R.L.; Hutchins, G.M.; Sack, G.H., Jr; Ridolfi, R.L. Unusual cardiac, renal and pulmonary involvement in Gauchers disease. Intersitial glucocerebroside accumulation, pulmonary hypertension and fatal bone marrow embolization. Am. J. Med., 1978, 65(2), 352-360.
54. Halevi, R.; Davidovitz, M.; Mann, S.; Ben-Bassat, M.; Stark, H.; Eisenstein, B. Gauchers disease and mesangiocapillary glomerulonephritis in childhooda coincidence? Pediatr. Nephrol., 1993, 7(4), 438-440.
55. Siegal, A.; Gutman, A.; Shapiro, M.S.; Griffel, B. Renal involvement in Gauchers disease. Postgrad. Med. J., 1981, 57(668), 398-401.
56. Chander, P.N.; Nurse, H.M.; Pirani, C.L. Renal involvement in adult Gauchers disease after splenectomy. Arch. Pathol. Lab. Med., 1979, 103(9), 440-445.
57. Morimura, Y.; Hojo, H.; Abe, M.; Wakasa, H. Gauchers disease, type I (adult type), with massive involvement of the kidneys and lungs. Virchows Arch., 1994, 425(5), 537-540.
58. Sugita, M.; Iwamori, M.; Evans, J.; McCluer, R.H.; Dulaney, J.T.; Moser, H.W. High performance liquid chromatography of ceramides: application to analysis in human tissues and demonstration of ceramide excess in Farbers disease. J. Lipid Res., 1974, 15(3), 223-226.
59. Park, J.H.; Schuchm, E.H. Acid ceramidase and human disease. Biochim. Biophys. Acta., 2006, 1758, 2133-2138.
60. Alayoubi, A.M.; Wang, J.C.; Au, B.C.; Carpentier, S.; Garcia, V.; Dworski, S.; El-Ghamrasni, S.; Kirouac, K.N.; Exertier, M.J.; Xiong, Z.J.; Privé, G.G.; Simonaro, C.M.; Casas, J.; Fabrias, G.; Schuchman, E.H.; Turner, P.V.; Hakem, R.; Levade, T.; Medin, J.A. Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Mol. Med., 2013, 5(6), 827-842.
61. Sands, M.S. Farber disease: understanding a fatal childhood disorder and dissecting ceramide biology. EMBO Mol. Med., 2013, 5(6), 799-801.
62. Farina, F.; Cappello, F.; Todaro, M.; Bucchieri, F.; Peri, G.; Zummo, G.; Stassi, G. Involvement of caspase-3 and GD3 ganglioside in ceramide-induced apoptosis in Farber disease. J. Histochem. Cytochem., 2000, 48(1), 57-62.
63. Fujiwaki, T.; Hamanaka, S.; Koga, M.; Ishihara, T.; Nishikomori, R.; Kinoshita, E.; Furusho, K. A case of Farber disease. Acta Paediatr. Jpn., 1992, 34(1), 72-79.
64. Qualman, S.J.; Moser, H.W.; Valle, D.; Moser, A.E.; Antonarakis, S.E.; Boitnott, J.K.; Zinkham, W.H. Farber disease: pathologic diagnosis in sibs with phenotypic variability. Am. J. Med. Genet. Suppl., 1987, 3, 233-241.
65. McGovern, M.M.; Lippa, N.; Bagiella, E.; Schuchman, E.H.; Desnick, R.J.; Wasserstein, M.P. Morbidity and mortality in type B Niemann-Pick disease. Genet. Med., 2013, 15(8), 618-623.
66. Horinouchi, K.; Erlich, S.; Perl, D.P.; Ferlinz, K.; Bisgaier, C.L.; Sandhoff, K.; Desnick, R.J.; Stewart, C.L.; Schuchman, E.H. Acid sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease. Nat. Genet., 1995, 10(3), 288-293.
67. Wu, B.X.; Fan, J.; Boyer, N.P.; Jenkins, R.W.; Koutalos, Y.; Hannun, Y.A.; Crosson, C.E. Lack of Acid Sphingomyelinase Induces Age-Related Retinal Degeneration. PLoS One, 2015, 10(7), e0133032.
68. Zhang, H.; Wang, Y.; Gong, Z.; Li, X.; Qiu, W.; Han, L.; Ye, J.; Gu, X. Identification of a distinct mutation spectrum in the SMPD1 gene of Chinese patients with acid sphingomyelinase- deficient Niemann-Pick disease. Orphanet J. Rare Dis., 2013, 8, 15.
69. Vanier, M.T. Complex lipid trafficking in Niemann-Pick disease type C. J. Inherit. Metab. Dis., 2015, 38(1), 187-199.
70. Lopez, A.M.; Terpack, S.J.; Posey, K.S.; Liu, B.; Ramirez, C.M.; Turley, S.D. Systemic administration of 2- hydroxypropyl-β-cyclodextrin to symptomatic Npc1- deficient mice slows cholesterol sequestration in the major organs and improves liver function. Clin. Exp. Pharmacol. Physiol., 2014, 41(10), 780-787.
71. Vance, J.E.; Karten, B. Niemann-Pick C disease and mobilization of lysosomal cholesterol by cyclodextrin. J. Lipid Res., 2014, 55(8), 1609-1621.
72. Kawai, K.; Tsuchiyama, H.; Tabata, K. An autopsy case of Niemann-Pick disease. Acta Pathol. Jpn., 1973, 23(4), 837-846.
73. Elleder, M.; Jirásek, A.; Smíd, F. Niemann-Pick disease (Crockers type C): A histological study of the distribution and qualitative differences fo the storage process. Acta Neuropathol., 1975, 33(3), 191-200.
74. Philit, J.B.; Queffeulou, G.; Walker, F.; Gubler, M.C.; Dupuis, E.; Vrtovsnik, F.; Mignon, F. Membranoproliferative glomerulonephritis type II and Niemann-Pick disease type C. Nephrol. Dial. Transplant., 2002, 17(10), 1829-1831.
75. Paul, B.M.; Vanden Heuvel, G.B. Kidney: polycystic kidney disease. Wiley Interdiscip. Rev. Dev. Biol., 2014, 3(6), 465-487.
76. Kandasamy, Y.; Smith, R.; Lumbers, E.R.; Rudd, D. Nephrin - a biomarker of early glomerular injury. Biomark. Res., 2014, 2, 21.
77. Holmberg, C.; Jalanko, H. Congenital nephrotic syndrome and recurrence of proteinuria after renal transplantation. Pediatr. Nephrol., 2014, 29(12), 2309-2317.
78. Wang, Z.; Sun, Z.; Li, A.V.; Yarema, K.J. Roles for UDPGlcNAc 2-epimerase/ManNAc 6-kinase outside of sialic acid biosynthesis: modulation of sialyltransferase and BiP expression, GM3 and GD3 biosynthesis, proliferation, and apoptosis, and ERK1/2 phosphorylation. J. Biol. Chem., 2006, 281(37), 27016-27028.
79. Galeano, B.; Klootwijk, R.; Manoli, I.; Sun, M.; Ciccone, C.; Darvish, D.; Starost, M.F.; Zerfas, P.M.; Hoffmann, V.J.; Hoogstraten-Miller, S.; Krasnewich, D.M.; Gahl, W.A.; Huizing, M. Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine. J. Clin. Invest., 2007, 117(6), 1585-1594.
80. Holthöfer, H.; Reivinen, J.; Solin, M.L.; Haltia, A.; Miettinen, A. Decrease of glomerular disialogangliosides in puromycin nephrosis of the rat. Am. J. Pathol., 1996, 149(3), 1009-1015.
81. Reivinen, J.; Holthöfer, H.; Miettinen, A. A cell-type specific ganglioside of glomerular podocytes in rat kidney: an O-acetylated GD3. Kidney Int., 1992, 42(3), 624-631.
82. Lama, G.; Luongo, I.; Tirino, G.; Borriello, A.; Carangio, C.; Salsano, M.E. T-lymphocyte populations and cytokines in childhood nephrotic syndrome. Am. J. Kidney Dis., 2002, 39(5), 958-965.
83. Dumontet, C.; Rebbaa, A.; Portoukalian, J. Very low density lipoproteins and interleukin 2 enhance the immunogenicity of 9-O-acetyl-GD3 ganglioside in BALB/c mice. J. Immunol. Methods, 1997, 206(1-2), 115-123.
84. Jin, J.; Sison, K.; Li, C.; Tian, R.; Wnuk, M.; Sung, H.K.; Jeansson, M.; Zhang, C.; Tucholska, M.; Jones, N.; Kerjaschki, D.; Shibuya, M.; Fantus, I.G.; Nagy, A.; Gerber, H.P.; Ferrara, N.; Pawson, T.; Quaggin, S.E. Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function. Cell, 2012, 151(2), 384-399.
85. Kim, N.H.; Oh, J.H.; Seo, J.A.; Lee, K.W.; Kim, S.G.; Choi, K.M.; Baik, S.H.; Choi, D.S.; Kang, Y.S.; Han, S.Y.; Han, K.H.; Ji, Y.H.; Cha, D.R. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int., 2005, 67(1), 167-177.
86. Tamaoki, A.; Kikkawa, Y. [The role of sulfatides in autoimmunity in children with various glomerular disease]. Nippon Jinzo Gakkai Shi, 1991, 33(11), 1045-1054.
87. Seki, K.; Kikkawa, Y. [Studies on Hanganutziu-Deicher antibodies in renal diseases]. Nippon Jinzo Gakkai Shi, 1992, 34(2), 107-115.
88. Fornoni, A.; Sageshima, J.; Wei, C.; Merscher-Gomez, S.; Aguillon-Prada, R.; Jauregui, A.N.; Li, J.; Mattiazzi, A.; Ciancio, G.; Chen, L.; Zilleruelo, G.; Abitbol, C.; Chandar, J.; Seeherunvong, W.; Ricordi, C.; Ikehata, M.; Rastaldi, M.P.; Reiser, J.; Burke, G.W., III Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci. Transl. Med., 2011, 3(85), 85ra46.
89. Yoo, T.H.; Pedigo, C.E.; Guzman, J.; Correa-Medina, M.; Wei, C.; Villarreal, R.; Mitrofanova, A.; Leclercq, F.; Faul, C.; Li, J.; Kretzler, M.; Nelson, R.G.; Lehto, M.; Forsblom, C.; Groop, P.H.; Reiser, J.; Burke, G.W.; Fornoni, A.; Merscher, S. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. J. Am. Soc. Nephrol., 2015, 26(1), 133-147.
90. Pautz, A.; Franzen, R.; Dorsch, S.; Böddinghaus, B.; Briner, V.A.; Pfeilschifter, J.; Huwiler, A. Cross-talk between nitric oxide and superoxide determines ceramide formation and apoptosis in glomerular cells. Kidney Int., 2002, 61(3), 790-796.
91. Pastukhov, O.; Schwalm, S.; Römer, I.; Zangemeister-Wittke, U.; Pfeilschifter, J.; Huwiler, A. Ceramide kinase contributes to proliferation but not to prostaglandin E2 formation in renal mesangial cells and fibroblasts. Cell. Physiol. Biochem., 2014, 34(1), 119-133.
92. Kaneko, T.; Tsubakihara, Y.; Fushimi, H.; Yamaguchi, S.; Takabatake, Y.; Rakugi, H.; Kawakami, H.; Isaka, Y. Histochemical and immunoelectron microscopic analysis of ganglioside GM3 in human kidney. Clin. Exp. Nephrol., 2015, 19(3), 403-410.
93. Lee, S.; Ahn, S.H.; Baek, S.H.; Song, J.H.; Choo, Y.K.; Kwon, O.D.; Choi, B.K.; Jung, K.Y. Modulation of cell proliferation and hypertrophy by gangliosides in cultured human glomerular mesangial cells. Arch. Pharm. Res., 2005, 28(8), 948-955.
94. Tsuboi, N.; Utsunomiya, Y.; Kawamura, T.; Kikuchi, T.; Hosoya, T.; Ohno, T.; Yamada, H. Shedding of growthsuppressive gangliosides from glomerular mesangial cells undergoing apoptosis. Kidney Int., 2003, 63(3), 936-946.
95. Rho, Y.I.; Kwak, D.H.; Lee, S.; Ahn, S.H.; Baek, S.H.; Song, J.H.; Choo, Y.K.; Choi, B.K.; Jung, K.Y. Mechanism for the negative regulation of cell proliferation by ganglioside GM3 in high glucose-treated glomerular mesangial cells. Life Sci., 2004, 75(1), 51-62.
96. Matsuura, M.; Kikkawa, Y.; Akashi, K.; Kitagawa, T.; Inage, Z.; Iwamori, M.; Takimoto, T.; Iidaka, K.; Serisawa, T. Thyroid antigen-antibody nephritis: possible involvement of fucosyl-GM1 as the antigen. Endocrinol. Jpn., 1987, 34(4), 587-593.
97. Li, G.; Hu, R.; Kamijo, Y.; Nakajima, T.; Aoyama, T.; Ehara, T.; Shigematsu, H.; Kannagi, R.; Kyogashima, M.; Hara, A. Kidney dysfunction induced by protein overload nephropathy reduces serum sulfatide levels in mice. Nephrology (Carlton), 2009, 14(7), 658-662.
98. Zhang, X.; Nakajima, T.; Kamijo, Y.; Li, G.; Hu, R.; Kannagi, R.; Kyogashima, M.; Aoyama, T.; Hara, A. Acute kidney injury induced by protein-overload nephropathy down-regulates gene expression of hepatic cerebroside sulfotransferase in mice, resulting in reduction of liver and serum sulfatides. Biochem. Biophys. Res. Commun., 2009, 390(4), 1382-1388.
99. Hu, R.; Li, G.; Kamijo, Y.; Aoyama, T.; Nakajima, T.; Inoue, T.; Node, K.; Kannagi, R.; Kyogashima, M.; Hara, A. Serum sulfatides as a novel biomarker for cardiovascular disease in patients with end-stage renal failure. Glycoconj. J., 2007, 24(9), 565-571.
100. Yuzhe, H.; Kamijo, Y.; Hashimoto, K.; Harada, M.; Kanno, T.; Sugiyama, E.; Kyogashima, M.; Oguchi, T.; Nakajima, T.; Kanno, Y.; Aoyama, T. Serum sulfatide abnormality is associated with increased oxidative stress in hemodialysis patients. Hemodial. Int., 2015, 19(3), 429-438.
101. Kamijo, Y.; Wang, L.; Matsumoto, A.; Nakajima, T.; Hashimoto, K.; Higuchi, M.; Kyogashima, M.; Aoyama, T.; Hara, A. Long-term improvement of oxidative stress via kidney transplantation ameliorates serum sulfatide levels. Clin. Exp. Nephrol., 2012, 16(6), 959-967.
102. Yang, S.H.; Lee, J.P.; Jang, H.R.; Cha, R.H.; Han, S.S.; Jeon, U.S.; Kim, D.K.; Song, J.; Lee, D.S.; Kim, Y.S. Sulfatide- reactive natural killer T cells abrogate ischemiareperfusion injury. J. Am. Soc. Nephrol., 2011, 22(7), 1305-1314.
103. Afkarian, M. Diabetic kidney disease in children and adolescents. Pediatr. Nephrol., 2015, 30(1), 65-74.
104. Zador, I.Z.; Deshmukh, G.D.; Kunkel, R.; Johnson, K.; Radin, N.S.; Shayman, J.A. A role for glycosphingolipid accumulation in the renal hypertrophy of streptozotocininduced diabetes mellitus. J. Clin. Invest., 1993, 91(3), 797-803.
105. Liu, G.; Han, F.; Yang, Y.; Xie, Y.; Jiang, H.; Mao, Y.; Wang, H.; Wang, M.; Chen, R.; Yang, J.; Chen, J. Evaluation of sphingolipid metabolism in renal cortex of rats with streptozotocin-induced diabetes and the effects of rapamycin. Nephrol. Dial. Transplant., 2011, 26(5), 1493-1502.
106. Novak, A.; Režić Mužinić, N.; Cikeš Čulić, V.; Božić, J.; Tičinović Kurir, T.; Ferhatović, L.; Puljak, L.; Markotić, A. Renal distribution of ganglioside GM3 in rat models of types 1 and 2 diabetes. J. Physiol. Biochem., 2013, 69(4), 727-735.
107. Grove, K.J.; Voziyan, P.A.; Spraggins, J.M.; Wang, S.; Paueksakon, P.; Harris, R.C.; Hudson, B.G.; Caprioli, R.M. Diabetic nephropathy induces alterations in the glomerular and tubule lipid profiles. J. Lipid Res., 2014, 55(7), 1375-1385.
108. Subathra, M.; Korrapati, M.; Howell, L.A.; Arthur, J.M.; Shayman, J.A.; Schnellmann, R.G.; Siskind, L.J. Kidney glycosphingolipids are elevated early in diabetic nephropathy and mediate hypertrophy of mesangial cells. Am. J. Physiol. Renal Physiol., 2015, 309(3), F204-F215.
109. Kwak, D.H.; Rho, Y.I.; Kwon, O.D.; Ahan, S.H.; Song, J.H.; Choo, Y.K.; Kim, S.J.; Choi, B.K.; Jung, K.Y. Decreases of ganglioside GM3 in streptozotocin-induced diabetic glomeruli of rats. Life Sci., 2003, 72(17), 1997-2006.
110. Dekker, M.J.; Baker, C.; Naples, M.; Samsoondar, J.; Zhang, R.; Qiu, W.; Sacco, J.; Adeli, K. Inhibition of sphingolipid synthesis improves dyslipidemia in the dietinduced hamster model of insulin resistance: evidence for the role of sphingosine and sphinganine in hepatic VLDLapoB100 overproduction. Atherosclerosis, 2013, 228(1), 98-109.
111. Chavez, J.A.; Siddique, M.M.; Wang, S.T.; Ching, J.; Shayman, J.A.; Summers, S.A. Ceramides and glucosylceramides are independent antagonists of insulin signaling. J. Biol. Chem., 2014, 289(2), 723-734.
112. Galadari, S.; Rahman, A.; Pallichankandy, S.; Galadari, A.; Thayyullathil, F. Role of ceramide in diabetes mellitus: evidence and mechanisms. Lipids Health Dis., 2013, 12, 98.
113. Lennon, R.; Pons, D.; Sabin, M.A.; Wei, C.; Shield, J.P.; Coward, R.J.; Tavaré, J.M.; Mathieson, P.W.; Saleem, M.A.; Welsh, G.I. Saturated fatty acids induce insulin resistance in human podocytes: implications for diabetic nephropathy. Nephrol. Dial. Transplant., 2009, 24(11), 3288-3296.
114. Ene, C.D.; Penescu, M.; Anghel, A.; Neagu, M.; Budu, V.; Nicolae, I. Monitoring diabetic nephropathy by circulating gangliosides. J. Immunoassay Immunochem., 2016, 37(1), 68-79.
115. Kim, Y.S.; Kim, J.; Kim, C.S.; Sohn, E.J.; Lee, Y.M.; Jeong, I.H.; Kim, H.; Jang, D.S.; Kim, J.S. KIOM-79, an inhibitor of AGEs-protein cross-linking, prevents progression of nephropathy in Zucker diabetic fatty rats. Evid, Based Complement Alternat. Med., 2011, 2011, 761859.
116. Geoffroy, K.; Wiernsperger, N.; Lagarde, M.; El Bawab, S. Bimodal effect of advanced glycation end products on mesangial cell proliferation is mediated by neutral ceramidase regulation and endogenous sphingolipids. J. Biol. Chem., 2004, 279(33), 34343-34352.
117. Masson, E.; Troncy, L.; Ruggiero, D.; Wiernsperger, N.; Lagarde, M.; El Bawab, S. a-Series gangliosides mediate the effects of advanced glycation end products on pericyte and mesangial cell proliferation: a common mediator for retinal and renal microangiopathy? Diabetes, 2005, 54(1), 220-227.
118. Buschard, K.; Josefsen, K.; Horn, T.; Larsen, S.; Fredman, P. Sulphatide antigen in islets of Langerhans and in diabetic glomeruli, and anti-sulphatide antibodies in type 1 diabetes mellitus. APMIS, 1993, 101(12), 963-970.
119. Lech, M.; Anders, H.J. The pathogenesis of lupus nephritis. J. Am. Soc. Nephrol., 2013, 24(9), 1357-1366.
120. Georgiou, P.; Maroulakou, I.; Green, J.; Dantis, P.; Romanospica, V.; Kottaridis, S.; Lautenberger, J.; Watson, D.; Papas, T.; Fischinger, P.; Bhat, N. Expression of ets family of genes in systemic lupus erythematosus and Sjogrens syndrome. Int. J. Oncol., 1996, 9(1), 9-18.
121. Richard, E.M.; Thiyagarajan, T.; Bunni, M.A.; Basher, F.; Roddy, P.O.; Siskind, L.J.; Nietert, P.J.; Nowling, T.K. Reducing FLI1 levels in the MRL/lpr lupus mouse model impacts T cell function by modulating glycosphingolipid metabolism. PLoS One, 2013, 8(9), e75175.
122. Morshed, S.R.; Takahashi, T.; Savage, P.B.; Kambham, N.; Strober, S. β-galactosylceramide alters invariant natural killer T cell function and is effective treatment for lupus. Clin. Immunol., 2009, 132(3), 321-333.
123. Alpa, M.; Ferrero, B.; Cavallo, R.; Perna, A.; Naretto, C.; Gennaro, M.; Di Simone, D.; Bellizia, L.; Mansouri, M.; Rossi, D.; Modena, V.; Giachino, O.; Sena, L.M.; Roccatello, D. Anti-GM1 and anti-sulfatide antibodies in patients with systemic lupus erythematosus, Sjögrens syndrome, mixed cryoglobulinemia and idiopathic systemic vasculitis. Clin. Exp. Rheumatol., 2007, 25(4), 556-562.
124. Khan, F.; Proulx, F.; Lingwood, C.A. Detergent-resistant globotriaosyl ceramide may define verotoxin/glomerulirestricted hemolytic uremic syndrome pathology. Kidney Int., 2009, 75(11), 1209-1216.
125. Cheung, V.; Trachtman, H. Hemolytic uremic syndrome: toxins, vessels, and inflammation. Front. Med. (Lausanne), 2014, 1, 42.
126. Ray, P.E. Shiga-like toxins and HIV-1 go through glycosphingolipids and lipid rafts in renal cells. Kidney Int., 2009, 75(11), 1135-1137.
127. Obrig, T.G.; Seaner, R.M.; Bentz, M.; Lingwood, C.A.; Boyd, B.; Smith, A.; Narrow, W. Induction by sphingomyelinase of shiga toxin receptor and shiga toxin 2 sensitivity in human microvascular endothelial cells. Infect. Immun., 2003, 71(2), 845-849.
128. Silberstein, C.; Lucero, M.S.; Zotta, E.; Copeland, D.P.; Lingyun, L.; Repetto, H.A.; Ibarra, C. A glucosylceramide synthase inhibitor protects rats against the cytotoxic effects of shiga toxin 2. Pediatr. Res., 2011, 69(5 Pt 1), 390-394.
129. Sessa, A.; Meroni, M.; Battini, G.; Maglio, A.; Nebuloni, M.; Tosoni, A.; Panichi, V.; Bertagnolio, B. Renal transplantation in patients with Fabry disease. Nephron, 2002, 91(2), 348-351.
130. Cochat, P.; Fargue, S.; Mestrallet, G.; Jungraithmayr, T.; Koch-Nogueira, P.; Ranchin, B.; Zimmerhackl, L.B. Disease recurrence in paediatric renal transplantation. Pediatr. Nephrol., 2009, 24(11), 2097-2108.
131. Ponticelli, C.; Moroni, G.; Glassock, R.J. Recurrence of secondary glomerular disease after renal transplantation. Clin. J. Am. Soc. Nephrol., 2011, 6(5), 1214-1221.
132. Tasaki, M.; Shimizu, A.; Hanekamp, I.; Torabi, R.; Villani, V.; Yamada, K. Rituximab treatment prevents the early development of proteinuria following pig-to-baboon xenokidney transplantation. J. Am. Soc. Nephrol., 2014, 25(4), 737-744.
133. Takahashi, Y.; Ikezumi, Y.; Saitoh, A. Rituximab protects podocytes and exerts anti-proteinuric effects in rat adriamycin- induced nephropathy independent of B-lymphocytes. Nephrology (Carlton), 2017, 22(1), 49-57.
134. Bezombes, C.; Grazide, S.; Garret, C.; Fabre, C.; Quillet-Mary, A.; Müller, S.; Jaffrézou, J.P.; Laurent, G. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood, 2004, 104(4), 1166-1173.
135. Chaudhuri, A.; Kambham, N.; Sutherland, S.; Grimm, P.; Alexander, S.; Concepcion, W.; Sarwal, M.; Wong, C. Rituximab treatment for recurrence of nephrotic syndrome in a pediatric patient after renal transplantation for congenital nephrotic syndrome of Finnish type. Pediatr. Transplant., 2012, 16(5), E183-E187.
136. Koch, A.; Pfeilschifter, J.; Huwiler, A. Sphingosine 1- phosphate in renal diseases. Cell. Physiol. Biochem., 2013, 31(6), 745-760.
137. Maceyka, M.; Sankala, H.; Hait, N.C.; Le Stunff, H.; Liu, H.; Toman, R.; Collier, C.; Zhang, M.; Satin, L.S.; Merrill, A.H., Jr; Milstien, S.; Spiegel, S. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J. Biol. Chem., 2005, 280(44), 37118-37129.
138. Hanafusa, N.; Yatomi, Y.; Yamada, K.; Hori, Y.; Nangaku, M.; Okuda, T.; Fujita, T.; Kurokawa, K.; Fukagawa, M. Sphingosine 1-phosphate stimulates rat mesangial cell proliferation from outside the cells. Nephrol. Dial. Transplant., 2002, 17(4), 580-586.
139. Schwalm, S.; Timcheva, T.M.; Filipenko, I.; Ebadi, M.; Hofmann, L.P.; Zangemeister-Wittke, U.; Pfeilschifter, J.; Huwiler, A. Sphingosine kinase 2 deficiency increases proliferation and migration of renal mouse mesangial cells and fibroblasts. Biol. Chem., 2015, 396(6-7), 813-825.
140. Zhong, Y.; Wang, K.; Zhang, X.; Cai, X.; Chen, Y.; Deng, Y. Nephrokeli, a Chinese herbal formula, may improve IgA nephropathy through regulation of the sphingosine-1- phosphate pathway. PLoS One, 2015, 10(1), e0116873.
141. Japtok, L.; Schmitz, E.I.; Fayyaz, S.; Krämer, S.; Hsu, L.J.; Kleuser, B. Sphingosine 1-phosphate counteracts insulin phosphate receptor subtype 2. FASEB J., 2015, 29(8), 3357-3369.
142. Bekpinar, S.; Yenidunya, G.; Gurdol, F.; Unlucerci, Y.; Aycan-Ustyol, E.; Dinccag, N. The effect of nephropathy on plasma sphingosine 1-phosphate concentrations in patients with type 2 diabetes. Clin. Biochem., 2015, 48(18), 1264-1267.
143. Denimal, D.; Pais de Barros, J.P.; Petit, J.M.; Bouillet, B.; Vergès, B.; Duvillard, L. Significant abnormalities of the HDL phosphosphingolipidome in type 1 diabetes despite normal HDL cholesterol concentration. Atherosclerosis, 2015, 241(2), 752-760.
144. Brinck, J.W.; Thomas, A.; Lauer, E.; Jornayvaz, F.R.; Brulhart-Meynet, M.C.; Prost, J.C.; Pataky, Z.; Löfgren, P.; Hoffstedt, J.; Eriksson, M.; Pramfalk, C.; Morel, S.; Kwak, B.R.; van Eck, M.; James, R.W.; Frias, M.A. Diabetes mellitus is associated with reduced high-density lipoprotein sphingosine-1-phosphate content and impaired high-density lipoprotein cardiac cell protection. Arterioscler. Thromb. Vasc. Biol., 2016, 36(5), 817-824.
145. Tong, X.; Peng, H.; Liu, D.; Ji, L.; Niu, C.; Ren, J.; Pan, B.; Hu, J.; Zheng, L.; Huang, Y. High-density lipoprotein of patients with type 2 diabetes mellitus upregulates cyclooxgenase- 2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1- phosphate. Cardiovasc. Diabetol., 2013, 12, 27.
146. Awad, A.S.; Rouse, M.D.; Khutsishvili, K.; Huang, L.; Bolton, W.K.; Lynch, K.R.; Okusa, M.D. Chronic sphingosine 1-phosphate 1 receptor activation attenuates earlystage diabetic nephropathy independent of lymphocytes. Kidney Int., 2011, 79(10), 1090-1098.
147. Watson, L.; Tullus, K.; Marks, S.D.; Holt, R.C.; Pilkington, C.; Beresford, M.W. Increased serum concentration of sphingosine-1-phosphate in juvenile-onset systemic lupus erythematosus. J. Clin. Immunol., 2012, 32(5), 1019-1025.
148. Ando, S.; Amano, H.; Amano, E.; Minowa, K.; Watanabe, T.; Nakano, S.; Nakiri, Y.; Morimoto, S.; Tokano, Y.; Lin, Q.; Hou, R.; Ohtsuji, M.; Tsurui, H.; Hirose, S.; Takasaki, Y. FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice. Biochem. Biophys. Res. Commun., 2010, 394(3), 804-810.
149. Snider, A.J.; Ruiz, P.; Obeid, L.M.; Oates, J.C. Inhibition of sphingosine kinase-2 in a murine model of lupus nephritis. PLoS One, 2013, 8(1), e53521.
150. Wenderfer, S.E.; Stepkowski, S.M.; Braun, M.C. Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist. Kidney Int., 2008, 74(10), 1319-1326.
151. Ni, H.; Chen, J.; Pan, M.; Zhang, M.; Zhang, J.; Chen, P.; Liu, B. FTY720 prevents progression of renal fibrosis by inhibiting renal microvasculature endothelial dysfunction in a rat model of chronic kidney disease. J. Mol. Histol., 2013, 44(6), 693-703.
152. El-Shewy, H.M.; Sohn, M.; Wilson, P.; Lee, M.H.; Hammad, S.M.; Luttrell, L.M.; Jaffa, A.A. Low-density lipoprotein induced expression of connective tissue growth factor via transactivation of sphingosine 1-phosphate receptors in mesangial cells. Mol. Endocrinol., 2012, 26(5), 833-845.
153. Ishizawa, S.; Takahashi-Fujigasaki, J.; Kanazawa, Y.; Matoba, K.; Kawanami, D.; Yokota, T.; Iwamoto, T.; Tajima, N.; Manome, Y.; Utsunomiya, K. Sphingosine-1-phosphate induces differentiation of cultured renal tubular epithelial cells under Rho kinase activation via the S1P2 receptor. Clin. Exp. Nephrol., 2014, 18(6), 844-852.
154. Xu, M.; Liu, D.; Ding, L.H.; Ma, K.L.; Wu, M.; Lv, L.L.; Wen, Y.; Liu, H.; Tang, R.N.; Liu, B.C. FTY720 inhibits tubulointerstitial inflammation in albumin overload-induced nephropathy of rats via the Sphk1 pathway. Acta Pharmacol. Sin., 2014, 35(12), 1537-1545.
155. Bajwa, A.; Rosin, D.L.; Chroscicki, P.; Lee, S.; Dondeti, K.; Ye, H.; Kinsey, G.R.; Stevens, B.K.; Jobin, K.; Kenwood, B.M.; Hoehn, K.L.; Lynch, K.R.; Okusa, M.D. Sphingosine 1-phosphate receptor-1 enhances mitochondrial function and reduces cisplatin-induced tubule injury. J. Am. Soc. Nephrol., 2015, 26(4), 908-925.
156. Thangada, S.; Shapiro, L.H.; Silva, C.; Yamase, H.; Hla, T.; Ferrer, F.A. Treatment with the immunomodulator FTY720 (fingolimod) significantly reduces renal inflammation in murine unilateral ureteral obstruction. J. Urol., 2014, 191(5)(Suppl.), 1508-1516.
157. Sola, A.; Weigert, A.; Jung, M.; Vinuesa, E.; Brecht, K.; Weis, N.; Brüne, B.; Borregaard, N.; Hotter, G. Sphingosine- 1-phosphate signalling induces the production of Lcn-2 by macrophages to promote kidney regeneration. J. Pathol., 2011, 225(4), 597-608.
158. Ballermann, B.J.; Obeidat, M. Tipping the balance from angiogenesis to fibrosis in CKD. Kidney Int. Suppl. (2011), 2014, 4(1), 45-52.
159. Fliser, D.; Wiecek, A.; Suleymanlar, G.; Ortiz, A.; Massy, Z.; Lindholm, B.; Martinez-Castelao, A.; Agarwal, R.; Jager, K.J.; Dekker, F.W.; Blankestijn, P.J.; Goldsmith, D.; Covic, A.; London, G.; Zoccali, C. for EUropean REnal and CArdiovascular Medicine working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). The dysfunctional endothelium in CKD and in cardiovascular disease: mapping the origin(s) of cardiovascular problems in CKD and of kidney disease in cardiovascular conditions for a research agenda. Kidney Int. Suppl., 2011, 2011(1), 6-9.
160. Guerrot, D.; Dussaule, J.C.; Kavvadas, P.; Boffa, J.J.; Chadjichristos, C.E.; Chatziantoniou, C. Progression of renal fibrosis: the underestimated role of endothelial alterations. Fibrogenesis Tissue Repair, 2012, 5(Suppl. 1), S15.
161. Huwiler, A.; Dorsch, S.; Briner, V.A.; van den Bosch, H.; Pfeilschifter, J. Nitric oxide stimulates chronic ceramide formation in glomerular endothelial cells. Biochem. Biophys. Res. Commun., 1999, 258(1), 60-65.
162. Huwiler, A.; Böddinghaus, B.; Pautz, A.; Dorsch, S.; Franzen, R.; Briner, V.A.; Brade, V.; Pfeilschifter, J. Superoxide potently induces ceramide formation in glomerular endothelial cells. Biochem. Biophys. Res. Commun., 2001, 284(2), 404-410.
163. Yi, F.; Jin, S.; Zhang, F.; Xia, M.; Bao, J.X.; Hu, J.; Poklis, J.L.; Li, P.L. Formation of lipid raft redox signalling platforms in glomerular endothelial cells: an early event of homocysteine- induced glomerular injury. J. Cell. Mol. Med., 2009, 13(9B), 3303-3314.
164. Symons, J.D.; Abel, E.D. Lipotoxicity contributes to endothelial dysfunction: a focus on the contribution from ceramide. Rev. Endocr. Metab. Disord., 2013, 14(1), 59-68.
165. Warnier, M.; Römer, W.; Geelen, J.; Lesieur, J.; Amessou, M.; van den Heuvel, L.; Monnens, L.; Johannes, L. Trafficking of Shiga toxin/Shiga-like toxin-1 in human glomerular microvascular endothelial cells and human mesangial cells. Kidney Int., 2006, 70(12), 2085-2091.
166. Ham, A.; Kim, M.; Kim, J.Y.; Brown, K.M.; Fruttiger, M.; DAgati, V.D.; Lee, H.T. Selective deletion of the endothelial sphingosine-1-phosphate 1 receptor exacerbates kidney ischemia-reperfusion injury. Kidney Int., 2014, 85(4), 807-823.
167. Zhang, G.; Yang, L.; Kim, G.S.; Ryan, K.; Lu, S.; ODonnell, R.K.; Spokes, K.; Shapiro, N.; Aird, W.C.; Kluk, M.J.; Yano, K.; Sanchez, T. Critical role of sphingosine-1- phosphate receptor 2 (S1PR2) in acute vascular inflammation. Blood, 2013, 122(3), 443-455.
168. Imasawa, T.; Kitamura, H.; Ohkawa, R.; Satoh, Y.; Miyashita, A.; Yatomi, Y. Unbalanced expression of sphingosine 1-phosphate receptors in diabetic nephropathy. Exp. Toxicol. Pathol., 2010, 62(1), 53-60.
169. Cantalupo, A.; Zhang, Y.; Kothiya, M.; Galvani, S.; Obinata, H.; Bucci, M.; Giordano, F.J.; Jiang, X.C.; Hla, T.; Di Lorenzo, A. Nogo-B regulates endothelial sphingolipid homeostasis to control vascular function and blood pressure. Nat. Med., 2015, 21(9), 1028-1037.
170. Zhao, J.; Singleton, P.A.; Brown, M.E.; Dudek, S.M.; Garcia, J.G. Phosphotyrosine protein dynamics in cell membrane rafts of sphingosine-1-phosphate-stimulated human endothelium: role in barrier enhancement. Cell. Signal., 2009, 21(12), 1945-1960.
171. Abadir, P.M.; Walston, J.D.; Carey, R.M. Subcellular characteristics of functional intracellular renin-angiotensin systems. Peptides, 2012, 38(2), 437-445.
172. Durvasula, R.V.; Shankland, S.J. Activation of a local renin angiotensin system in podocytes by glucose. Am. J. Physiol. Renal Physiol., 2008, 294(4), F830-F839.
173. Camargo de Andrade, M.C.; Di Marco, G.S.; de Paulo Castro Teixeira, V.; Mortara, R.A.; Sabatini, R.A.; Pesquero, J.B.; Boim, M.A.; Carmona, A.K.; Schor, N.; Casarini, D.E. Expression and localization of N-domain ANG I-converting enzymes in mesangial cells in culture from spontaneously hypertensive rats. Am. J. Physiol. Renal Physiol., 2006, 290(2), F364-F375.
174. Peng, H.; Xing, Y.F.; Ye, Z.C.; Li, C.M.; Luo, P.L.; Li, M.; Lou, T.Q. High glucose induces activation of the local renin-angiotensin system in glomerular endothelial cells. Mol. Med. Rep., 2014, 9(2), 450-456.
175. Wennmann, D.O.; Hsu, H.H.; Pavenstädt, H. The reninangiotensin- aldosterone system in podocytes. Semin. Nephrol., 2012, 32(4), 377-384.
176. Hao, J.; Ren, L.; Zhang, L.; Kong, D.; Hao, L. Aldosteroneinduced inflammatory response of mesangial cells via angiotension II receptors. J. Renin Angiotensin Aldosterone Syst., 2015, 16(4), 739-748.
177. Yuan, Y.; Xu, X.; Zhao, C.; Zhao, M.; Wang, H.; Zhang, B.; Wang, N.; Mao, H.; Zhang, A.; Xing, C. The roles of oxidative stress, endoplasmic reticulum stress, and autophagy in aldosterone/mineralocorticoid receptor-induced podocyte injury. Lab. Invest., 2015, 95(12), 1374-1386.
178. Zhu, D.; Yu, H.; He, H.; Ding, J.; Tang, J.; Cao, D.; Hao, L. Spironolactone inhibits apoptosis in rat mesangial cells under hyperglycaemic conditions via the Wnt signalling pathway. Mol. Cell. Biochem., 2013, 380(1-2), 185-193.
179. Messmer, U.K.; Winkel, G.; Briner, V.A.; Pfeilschifter, J. Glucocorticoids potently block tumour necrosis factor-αand lipopolysaccharide-induced apoptotic cell death in bovine glomerular endothelial cells upstream of caspase 3 activation. Br. J. Pharmacol., 1999, 127(7), 1633-1640.
180. Yuan, Y.; Chen, Y.; Zhang, P.; Huang, S.; Zhu, C.; Ding, G.; Liu, B.; Yang, T.; Zhang, A. Mitochondrial dysfunction accounts for aldosterone-induced epithelial-tomesenchymal transition of renal proximal tubular epithelial cells. Free Radic. Biol. Med., 2012, 53(1), 30-43.
181. Adams, B.P.; Bose, H.S. Alteration in accumulated aldosterone synthesis as a result of N-terminal cleavage of aldosterone synthase. Mol. Pharmacol., 2012, 81(3), 465-474.
182. Wilson, B.A.; Nautiyal, M.; Gwathmey, T.M.; Rose, J.C.; Chappell, M.C. Evidence for a mitochondrial angiotensin- (1-7) system in the kidney. Am. J. Physiol. Renal Physiol., 2016, 310(7), F637-F645.
183. Novgorodov, S.A.; Riley, C.L.; Yu, J.; Keffler, J.A.; Clarke, C.J.; Van Laer, A.O.; Baicu, C.F.; Zile, M.R.; Gudz, T.I. Lactosylceramide contributes to mitochondrial dysfunction in diabetes. J. Lipid Res., 2016, 57(4), 546-562.
184. Schüll, S.; Günther, S.D.; Brodesser, S.; Seeger, J.M.; Tosetti, B.; Wiegmann, K.; Pongratz, C.; Diaz, F.; Witt, A.; Andree, M.; Brinkmann, K.; Krönke, M.; Wiesner, R.J.; Kashkar, H. Cytochrome c oxidase deficiency accelerates mitochondrial apoptosis by activating ceramide synthase 6. Cell. Death. Dis., 2015, 6, e1691.
185. Rajagopalan, V.; Canals, D.; Luberto, C.; Snider, J.; Voelkel-Johnson, C.; Obeid, L.M.; Hannun, Y.A. Nitric oxide induces degradation of the neutral ceramidase in rat renal mesangial cells and is counterregulated by protein kinase C. J. Biol. Chem., 2002, 277, 46184-46190.
186. Novgorodov, S.A.; Riley, C.L.; Yu, J.; Borg, K.T.; Hannun, Y.A.; Proia, R.L.; Kindy, M.S.; Gudz, T.I. Essential roles of neutral ceramidase and sphingosine in mitochondrial dysfunction due to traumatic brain injury. J. Biol. Chem., 2014, 289(19), 13142-13154.
187. Franzen, R.; Fabbro, D.; Aschrafi, A.; Pfeilschifter, J.; Huwiler, A. Nitric oxide induces degradation of the neutral ceramidase in rat renal mesangial cells and is counterregulated by protein kinase C. J. Biol. Chem., 2002, 277(48), 46184-46190.
188. Baylis, C. Nitric oxide deficiency in chronic kidney disease. Am. J. Physiol. Renal Physiol., 2008, 294(1), F1-F9.
189. Prabhakar, S.; Starnes, J.; Shi, S.; Lonis, B.; Tran, R. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J. Am. Soc. Nephrol., 2007, 18(11), 2945-2952.
190. Attia, D.M.; Feron, O.; Goldschmeding, R.; Radermakers, L.H.; Vaziri, N.D.; Boer, P.; Balligand, J.L.; Koomans, H.A.; Joles, J.A. Hypercholesterolemia in rats induces podocyte stress and decreases renal cortical nitric oxide synthesis via an angiotensin II type 1 receptor-sensitive mechanism. J. Am. Soc. Nephrol., 2004, 15(4), 949-957.
191. Lee, D.Y.; Wauquier, F.; Eid, A.A.; Roman, L.J.; Ghosh-Choudhury, G.; Khazim, K.; Block, K.; Gorin, Y. Nox4 NADPH oxidase mediates peroxynitrite-dependent uncoupling of endothelial nitric-oxide synthase and fibronectin expression in response to angiotensin II: role of mitochondrial reactive oxygen species. J. Biol. Chem., 2013, 288(40), 28668-28686.
192. Chen, W.G.; Zhou, T.T.; Zhou, P.; Li, X.W.; Wu, Z.; Zhang, K.Y.; Xing, J.C. Aldosterone-to-renin ratio acts as the predictor distinguishing the primary aldosteronism from chronic kidney disease. Int. J. Clin. Exp. Pathol., 2015, 8(6), 6901-6909.
193. Schwenk, M.H.; Hirsch, J.S.; Bomback, A.S. Aldosterone blockade in CKD: emphasis on pharmacology. Adv. Chronic Kidney Dis., 2015, 22(2), 123-132.
194. Queisser, N.; Schupp, N. Aldosterone, oxidative stress, and NF-κB activation in hypertension-related cardiovascular and renal diseases. Free Radic. Biol. Med., 2012, 53(2), 314-327.
195. Pechanova, O.; Matuskova, J.; Capikova, D.; Jendekova, L.; Paulis, L.; Simko, F. Effect of spironolactone and captopril on nitric oxide and S-nitrosothiol formation in kidney of LNAME- treated rats. Kidney Int., 2006, 70(1), 170-176.
196. Mejía-Vilet, J.M.; Ramírez, V.; Cruz, C.; Uribe, N.; Gamba, G.; Bobadilla, N.A. Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am. J. Physiol. Renal Physiol., 2007, 293(1), F78-F86.
197. Berdyshev, E.V.; Gorshkova, I.; Skobeleva, A.; Bittman, R.; Lu, X.; Dudek, S.M.; Mirzapoiazova, T.; Garcia, J.G.; Natarajan, V. FTY720 inhibits ceramide synthases and up regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells. J. Biol. Chem., 2009, 284(9), 5467-5477.
198. Laviad, E.L.; Albee, L.; Pankova-Kholmyansky, I.; Epstein, S.; Park, H.; Merrill, A.H., Jr; Futerman, A.H. Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J. Biol. Chem., 2008, 283(9), 5677-5684.
199. Brizuela, L.; Rábano, M.; Peña, A.; Gangoiti, P.; Macarulla, J.M.; Trueba, M.; Gómez-Muñoz, A. Sphingosine 1- phosphate: a novel stimulator of aldosterone secretion. J. Lipid Res., 2006, 47(6), 1238-1249.
200. Dilauro, M.; Burns, K.D. Angiotensin-(17) and its effects in the kidney. ScientificWorldJournal, 2009, 9, 522-535.
201. Aroor, A.R.; Demarco, V.G.; Jia, G.; Sun, Z.; Nistala, R.; Meininger, G.A.; Sowers, J.R. The role of tissue Renin-Angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness. Front. Endocrinol. (Lausanne), 2013, 4, 161.
202. Rüster, C.; Wolf, G. Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis. J. Am. Soc. Nephrol., 2011, 22(7), 1189-1199.
203. Kok, H.M.; Falke, L.L.; Goldschmeding, R.; Nguyen, T.Q. Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease. Nat. Rev. Nephrol., 2014, 10(12), 700-711.
204. Rutkowski, B.; Tylicki, L. Nephroprotective action of renin-angiotensin-aldosterone system blockade in chronic kidney disease patients: the landscape after ALTITUDE and VA NEPHRON-D trails. J. Ren. Nutr., 2015, 25(2), 194-200.
205. Efrati, S.; Berman, S.; Goldfinger, N.; Erez, N.; Averbukh, Z.; Golik, A.; Rotter, V.; Weissgarten, J. Enhanced angiotensin II production by renal mesangium is responsible for apoptosis/proliferation of endothelial and epithelial cells in a model of malignant hypertension. J. Hypertens., 2007, 25(5), 1041-1052.
206. Berman, S.; Abu Hamad, R.; Efrati, S. Mesangial cells are responsible for orchestrating the renal podocytes injury in the context of malignant hypertension. Nephrology (Carlton), 2013, 18(4), 292-298.
207. Jing, X.; Huang, W.H.; Tang, Y.J.; Wang, Y.Q.; Li, H.; Tian, Y.Y.; Chen, Y.; Zhou, H.H.; Ouyang, D.S. Eucommia ulmoides oliv. (du-zhong) lignans inhibit angiotensin iistimulated proliferation by affecting p21, p27, and bax expression in rat mesangial cells. Evid. Based Complement Alternat. Med., 2015, 2015, 987973.
208. Brown, N.J. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat. Rev. Nephrol., 2013, 9(8), 459-469.
209. Bai, M.; Che, R.; Zhang, Y.; Yuan, Y.; Zhu, C.; Ding, G.; Jia, Z.; Huang, S.; Zhang, A. Reactive oxygen speciesinitiated autophagy opposes aldosterone-induced podocyte injury. Am. J. Physiol. Renal Physiol., 2016, 310(7), F669-F678.
210. Bertocchio, J.P.; Warnock, D.G.; Jaisser, F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int., 2011, 79(10), 1051-1060.
211. Bolignano, D.; Palmer, S.C.; Navaneethan, S.D.; Strippoli, G.F. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst. Rev., 2014, (4), CD007004.
212. Sachse, A.; Wolf, G. Angiotensin II-induced reactive oxygen species and the kidney. J. Am. Soc. Nephrol., 2007, 18(9), 2439-2446.
213. Li, P.L.; Zhang, Y. Cross talk between ceramide and redox signaling: implications for endothelial dysfunction and renal disease. Handbook Exp. Pharmacol., 2013, 216(216), 171-197.
214. Leung, J.C.; Chan, L.Y.; Tang, S.C.; Lam, M.F.; Chow, C.W.; Lim, A.I.; Lai, K.N. Oxidative damages in tubular epithelial cells in IgA nephropathy: role of crosstalk between angiotensin II and aldosterone. J. Transl. Med., 2011, 9, 169.
215. Das, R.; Xu, S.; Nguyen, T.T.; Quan, X.; Choi, S.K.; Kim, S.J.; Lee, E.Y.; Cha, S.K.; Park, K.S. Transforming growth factor β1-induced apoptosis in podocytes via the extracellular signal-regulated kinase-mammalian target of rapamycin complex 1-NADPH oxidase 4 axis. J. Biol. Chem., 2015, 290(52), 30830-30842.
216. Loeffler, I.; Wolf, G. Transforming growth factor-β and the progression of renal disease. Nephrol. Dial. Transplant., 2014, 29(Suppl. 1), i37-i45.
217. Völzke, A.; Koch, A.; Meyer Zu Heringdorf, D.; Huwiler, A.; Pfeilschifter, J. Sphingosine 1-phosphate (S1P) induces COX-2 expression and PGE2 formation via S1P receptor 2 in renal mesangial cells. Biochim. Biophys. Acta, 2014, 1841, 11-21.
218. Hus-Citharel, A.; Bouby, N.; Frugière, A.; Bodineau, L.; Gasc, J.M.; Llorens-Cortes, C. Effect of apelin on glomerular hemodynamic function in the rat kidney. Kidney Int., 2008, 74(4), 486-494.
219. Colina, C.; Flores, A.; Rojas, H.; Acosta, A.; Castillo, C.; Garrido, Mdel.R.; Israel, A.; DiPolo, R.; Benaim, G. Ceramide increase cytoplasmic Ca2+ concentration in Jurkat T cells by liberation of calcium from intracellular stores and activation of a store-operated calcium channel. Arch. Biochem. Biophys., 2005, 436(2), 333-345.
220. Rajapakse, N.W.; De Miguel, C.; Das, S.; Mattson, D.L. Exogenous L-arginine ameliorates angiotensin II-induced hypertension and renal damage in rats. Hypertension, 2008, 52(6), 1084-1090.
221. Li, Q.; Chen, B.; Zeng, C.; Fan, A.; Yuan, Y.; Guo, X.; Huang, X.; Huang, Q. Differential activation of receptors and signal pathways upon stimulation by different doses of sphingosine-1-phosphate in endothelial cells. Exp. Physiol., 2015, 100(1), 95-107.
222. Guan, Z.; Singletary, S.T.; Cook, A.K.; Hobbs, J.L.; Pollock, J.S.; Inscho, E.W. Sphingosine-1-phosphate evokes unique segment-specific vasoconstriction of the renal microvasculature. J. Am. Soc. Nephrol., 2014, 25(8), 1774-1785.
223. Igarashi, J.; Michel, T. Sphingosine-1-phosphate and modulation of vascular tone. Cardiovasc. Res., 2009, 82(2), 212-220.
224. Su, J.B. Vascular endothelial dysfunction and pharmacological treatment. World J. Cardiol., 2015, 7(11), 719-741.
225. Wilson, P.C.; Fitzgibbon, W.R.; Garrett, S.M.; Jaffa, A.A.; Luttrell, L.M.; Brands, M.W.; El-Shewy, H.M. Inhibition of sphingosine kinase 1 ameliorates angiotensin II-induced hypertension and inhibits transmembrane calcium entry via store-operated calcium channel. Mol. Endocrinol., 2015, 29(6), 896-908.
226. Furuya, H.; Wada, M.; Shimizu, Y.; Yamada, P.M.; Hannun, Y.A.; Obeid, L.M.; Kawamori, T. Effect of sphingosine kinase 1 inhibition on blood pressure. FASEB J., 2013, 27(2), 656-664.
227. Kim, J.Y.; Lim, S.W.; Li, C.; Kim, J.S.; Ahn, K.O.; Yang, H.J.; Choi, B.S.; Kim, Y.S.; Kim, J.; Bang, B.K.; Yang, C.W. Effect of FTY720 on chronic cyclosporine nephropathy in rats. Transplantation, 2005, 80(9), 1323-1330.
228. Hernáandez-Corbacho, M.J.; Salama, M.F.; Canals, D.; Senkal, C.E.; Obeid, L.M. Sphingolipids in mitochondria. Biochim. Biophys. Acta., 2017, 1862, 56-68.
229. Das, A.M.; Naim, H.Y. Biochemical basis of Fabry disease with emphasis on mitochondrial function and protein trafficking. Adv. Clin. Chem., 2009, 49, 57-71.
230. Gegg, M.E.; Schapira, A.H. Mitochondrial dysfunction associated with glucocerebrosidase deficiency. Neurobiol. Dis., 2016, 90, 43-50.
231. Yi, F.; Zhang, A.Y.; Janscha, J.L.; Li, P.L.; Zou, A.P. Homocysteine activates NADH/NADPH oxidase through ceramide- stimulated Rac GTPase activity in rat mesangial cells. Kidney Int., 2004, 66(5), 1977-1987.
232. Rölz, W.; Xin, C.; Ren, S.; Pfeilschifter, J.; Huwiler, A. Interleukin-1β inhibits ATP-induced protein kinase B activation in renal mesangial cells by two different mechanisms: the involvement of nitric oxide and ceramide. Br. J. Pharmacol., 2003, 138(3), 461-468.
233. Kogot-Levin, A.; Saada, A. Ceramide and the mitochondrial respiratory chain. Biochimie, 2014, 100, 88-94.
234. Novgorodov, S.A.; Szulc, Z.M.; Luberto, C.; Jones, J.A.; Bielawski, J.; Bielawska, A.; Hannun, Y.A.; Obeid, L.M. Positively charged ceramide is a potent inducer of mitochondrial permeabilization. J. Biol. Chem., 2005, 280(16), 16096-16105.
235. Siskind, L.J.; Feinstein, L.; Yu, T.; Davis, J.S.; Jones, D.; Choi, J.; Zuckerman, J.E.; Tan, W.; Hill, R.B.; Hardwick, J.M.; Colombini, M. Anti-apoptotic Bcl-2 family proteins disassemble ceramide channels. J. Biol. Chem., 2008, 283(11), 6622-6630.
236. Beverly, L.J.; Howell, L.A.; Hernandez-Corbacho, M.; Casson, L.; Chipuk, J.E.; Siskind, L.J. BAK activation is necessary and sufficient to drive ceramide synthasedependent ceramide accumulation following inhibition of BCL2-like proteins. Biochem. J., 2013, 452(1), 111-119.
237. Abou-Ghali, M.; Stiban, J. Regulation of ceramide channel formation and disassembly: Insights on the initiation of apoptosis. Saudi J. Biol. Sci., 2015, 22(6), 760-772.
238. Pastorino, J.G.; Tafani, M.; Rothman, R.J.; Marcinkeviciute, A.; Hoek, J.B.; Farber, J.L. Functional consequences of the sustained or transient activation by Bax of the mitochondrial permeability transition pore. J. Biol. Chem., 1999, 274(44), 31734-31739.
239. Marténez-Abundis, E.; García, N.; Correa, F.; Franco, M.; Zazueta, C. Changes in specific lipids regulate BAXinduced mitochondrial permeability transition. FEBS J., 2007, 274(24), 6500-6510.
240. Ganesan, V.; Perera, M.N.; Colombini, D.; Datskovskiy, D.; Chadha, K.; Colombini, M. Ceramide and activated Bax act synergistically to permeabilize the mitochondrial outer membrane. Apoptosis, 2010, 15(5), 553-562.
241. Kashkar, H.; Wiegmann, K.; Yazdanpanah, B.; Haubert, D.; Krönke, M. Acid sphingomyelinase is indispensable for UV light-induced Bax conformational change at the mitochondrial membrane. J. Biol. Chem., 2005, 280(21), 20804-20813.
242. Chipuk, J.E.; McStay, G.P.; Bharti, A.; Kuwana, T.; Clarke, C.J.; Siskind, L.J.; Obeid, L.M.; Green, D.R. Sphingolipid metabolism cooperates with BAK and BAX to promote the mitochondrial pathway of apoptosis. Cell, 2012, 148(5), 988-1000.
243. Scharstuhl, A.; Mutsaers, H.A.; Pennings, S.W.; Russel, F.G.; Wagener, F.A. Involvement of VDAC, Bax and ceramides in the efflux of AIF from mitochondria during curcumin- induced apoptosis. PLoS One, 2009, 4(8), e6688.
244. Yamaguchi, K.; Hata, K.; Koseki, K.; Shiozaki, K.; Akita, H.; Wada, T.; Moriya, S.; Miyagi, T. Evidence for mitochondrial localization of a novel human sialidase (NEU4). Biochem. J., 2005, 390(Pt 1), 85-93.
245. Malisan, F.; Franchi, L.; Tomassini, B.; Ventura, N.; Condò, I.; Rippo, M.R.; Rufini, A.; Liberati, L.; Nachtigall, C.; Kniep, B.; Testi, R. Acetylation suppresses the proapoptotic activity of GD3 ganglioside. J. Exp. Med., 2002, 196(12), 1535-1541.
246. Colell, A.; García-Ruiz, C.; Mari, M.; Fernández-Checa, J.C. Mitochondrial permeability transition induced by reactive oxygen species is independent of cholesterol-regulated membrane fluidity. FEBS Lett., 2004, 560(1-3), 63-68.
247. Scorrano, L.; Petronilli, V.; Di Lisa, F.; Bernardi, P. Commitment to apoptosis by GD3 ganglioside depends on opening of the mitochondrial permeability transition pore. J. Biol. Chem., 1999, 274(32), 22581-22585.
248. García-Ruiz, C.; Colell, A.; París, R.; Fernández-Checa, J.C. Direct interaction of GD3 ganglioside with mitochondria generates reactive oxygen species followed by mitochondrial permeability transition, cytochrome c release, and caspase activation. FASEB J., 2000, 14(7), 847-858.
249. Fragaki, K.; Ait-El-Mkadem, S.; Chaussenot, A.; Gire, C.; Mengual, R.; Bonesso, L.; Bénéteau, M.; Ricci, J.E.; Desquiret-Dumas, V.; Procaccio, V.; Rötig, A.; Paquis-Flucklinger, V. Refractory epilepsy and mitochondrial dysfunction due to GM3 synthase deficiency. Eur. J. Hum. Genet., 2013, 21(5), 528-534.
250. Higuchi, Y.; Miura, T.; Kajimoto, T.; Ohta, Y. Effects of disialoganglioside GD3 on the mitochondrial membrane potential. FEBS Lett., 2005, 579(14), 3009-3013.
251. Garofalo, T.; Tinari, A.; Matarrese, P.; Giammarioli, A.M.; Manganelli, V.; Ciarlo, L.; Misasi, R.; Sorice, M.; Malorni, W. Do mitochondria act as cargo boats in the journey of GD3 to the nucleus during apoptosis? FEBS Lett., 2007, 581(21), 3899-3903.
252. Siskind, L.J.; Mullen, T.D.; Romero Rosales, K.; Clarke, C.J.; Hernandez-Corbacho, M.J.; Edinger, A.L.; Obeid, L.M. The BCL-2 protein BAK is required for long-chain ceramide generation during apoptosis. J. Biol. Chem., 2010, 285(16), 11818-11826.
253. Rippo, M.R.; Malisan, F.; Ravagnan, L.; Tomassini, B.; Condo, I.; Costantini, P.; Susin, S.A.; Rufini, A.; Todaro, M.; Kroemer, G.; Testi, R. GD3 ganglioside directly targets mitochondria in a bcl-2-controlled fashion. FASEB J., 2000, 14(13), 2047-2054.
254. Rapizzi, E.; Pinton, P.; Szabadkai, G.; Wieckowski, M.R.; Vandecasteele, G.; Baird, G.; Tuft, R.A.; Fogarty, K.E.; Rizzuto, R. Recombinant expression of the voltagedependent anion channel enhances the transfer of Ca2+ microdomains to mitochondria. J. Cell Biol., 2002, 159(4), 613-624.
255. Roy, S.S.; Madesh, M.; Davies, E.; Antonsson, B.; Danial, N.; Hajnóczky, G. Bad targets the permeability transition pore independent of Bax or Bak to switch between Ca2+- dependent cell survival and death. Mol. Cell, 2009, 33(3), 377-388.
256. Garofalo, T.; Giammarioli, A.M.; Misasi, R.; Tinari, A.; Manganelli, V.; Gambardella, L.; Pavan, A.; Malorni, W.; Sorice, M. Lipid microdomains contribute to apoptosisassociated modifications of mitochondria in T cells. Cell Death Differ., 2005, 12(11), 1378-1389.
257. Granata, S.; Zaza, G.; Simone, S.; Villani, G.; Latorre, D.; Pontrelli, P.; Carella, M.; Schena, F.P.; Grandaliano, G.; Pertosa, G. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics, 2009, 10, 388.
258. Tucker, P.S.; Scanlan, A.T.; Dalbo, V.J. Chronic kidney disease influences multiple systems: describing the relationship between oxidative stress, inflammation, kidney damage, and concomitant disease. Oxid. Med. Cell. Longev., 2015, 2015, 806358.
259. Shen, J.S.; Meng, X.L.; Moore, D.F.; Quirk, J.M.; Shayman, J.A.; Schiffmann, R.; Kaneski, C.R. Globotriaosylce ramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol. Genet. Metab., 2008, 95(3), 163-168.
260. Vázquez, M.C.; Balboa, E.; Alvarez, A.R.; Zanlungo, S. Oxidative stress: a pathogenic mechanism for Niemann-Pick type C disease. Oxid. Med. Cell. Longev., 2012, 2012, 205713.
261. Cleeter, M.W.; Chau, K.Y.; Gluck, C.; Mehta, A.; Hughes, D.A.; Duchen, M.; Wood, N.W.; Hardy, J.; Mark Cooper, J.; Schapira, A.H. Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem. Int., 2013, 62(1), 1-7.
262. García-Ruiz, C.; Colell, A.; París, R.; Fernéndez-Checa, J.C. Direct interaction of GD3 ganglioside with mitochondria generates reactive oxygen species followed by mitochondrial permeability transition, cytochrome c release, and caspase activation. FASEB J., 2000, 14(7), 847-858.
263. Therade-Matharan, S.; Laemmel, E.; Carpentier, S.; Obata, Y.; Levade, T.; Duranteau, J.; Vicaut, E. Reactive oxygen species production by mitochondria in endothelial cells exposed to reoxygenation after hypoxia and glucose depletion is mediated by ceramide. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2005, 289(6), R1756-R1762.
264. Boini, K.M.; Xia, M.; Li, C.; Zhang, C.; Payne, L.P.; Abais, J.M.; Poklis, J.L.; Hylemon, P.B.; Li, P.L. Acid sphingomyelinase gene deficiency ameliorates the hyperhomocysteinemia- induced glomerular injury in mice. Am. J. Pathol., 2011, 179(5), 2210-2219.
265. Stiban, J.; Caputo, L.; Colombini, M. Ceramide synthesis in the endoplasmic reticulum can permeabilize mitochondria to proapoptotic proteins. J. Lipid Res., 2008, 49(3), 625-634.
266. Ardail, D.; Popa, I.; Bodennec, J.; Louisot, P.; Schmitt, D.; Portoukalian, J. The mitochondria-associated endoplasmicreticulum subcompartment (MAM fraction) of rat liver contains highly active sphingolipid-specific glycosyltransferases. Biochem. J., 2003, 371(Pt 3), 1013-1019.
267. Sano, R.; Annunziata, I.; Patterson, A.; Moshiach, S.; Gomero, E.; Opferman, J.; Forte, M.; dAzzo, A. GM1- ganglioside accumulation at the mitochondria-associated ER membranes links ER stress to Ca2+-dependent mitochondrial apoptosis. Mol. Cell, 2009, 36(3), 500-511.
268. Bononi, A.; Missiroli, S.; Poletti, F.; Suski, J.M.; Agnoletto, C.; Bonora, M.; De Marchi, E.; Giorgi, C.; Marchi, S.; Patergnani, S.; Rimessi, A.; Wieckowski, M.R.; Pinton, P. Mitochondria- associated membranes (MAMs) as hotspot Ca(2+) signaling units. Adv. Exp. Med. Biol., 2012, 740, 411-437.
269. dAzzo, A.; Tessitore, A.; Sano, R. Gangliosides as apoptotic signals in ER stress response. Cell Death Differ., 2006, 13(3), 404-414.
270. Vitner, E.B.; Platt, F.M.; Futerman, A.H. Common and uncommon pathogenic cascades in lysosomal storage diseases. J. Biol. Chem., 2010, 285(27), 20423-20427.
271. Mangolini, A.; de Stephanis, L.; Aguiari, G. Role of calcium in polycystic kidney disease: From signaling to pathology. World. J. Nephrol., 2016, 5(1), 76-83.
272. Strub, G.M.; Paillard, M.; Liang, J.; Gomez, L.; Allegood, J.C.; Hait, N.C.; Maceyka, M.; Price, M.M.; Chen, Q.; Simpson, D.C.; Kordula, T.; Milstien, S.; Lesnefsky, E.J.; Spiegel, S. Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration. FASEB J., 2011, 25(2), 600-612.
273. White, C.R.; Giordano, S.; Anantharamaiah, G.M. Highdensity lipoprotein, mitochondrial dysfunction and cell survival mechanisms. Chem. Phys. Lipids., 2016, 199, 161-169.
274. Betito, S.; Cuvillier, O. Regulation by sphingosine 1- phosphate of Bax and Bad activities during apoptosis in a MEK-dependent manner. Biochem. Biophys. Res. Commun., 2006, 340(4), 1273-1277.
275. Laychock, S.G.; Sessanna, S.M.; Lin, M.H.; Mastrandrea, L.D. Sphingosine 1-phosphate affects cytokine-induced apoptosis in rat pancreatic islet beta-cells. Endocrinology, 2006, 147(10), 4705-4712.
276. Qi, Y.; Chen, J.; Lay, A.; Don, A.; Vadas, M.; Xia, P. Loss of sphingosine kinase 1 predisposes to the onset of diabetes via promoting pancreatic β-cell death in diet-induced obese mice. FASEB J., 2013, 27(10), 4294-4304.
277. Huwiler, A.; Xin, C.; Brust, A.K.; Briner, V.A.; Pfeilschifter, J. Differential binding of ceramide to MEKK1 in glomerular endothelial and mesangial cells. Biochim. Biophys. Acta, 2004, 1636(2-3), 159-168.
278. Wilmer, W.A.; Dixon, C.L.; Hebert, C.; Lu, L.; Rovin, B.H. PPAR-α ligands inhibit H2O2-mediated activation of transforming growth factor-β1 in human mesangial cells. Antioxid. Redox Signal., 2002, 4(6), 877-884.
279. Das, R.; Xu, S.; Nguyen, T.T.; Quan, X.; Choi, S.K.; Kim, S.J.; Lee, E.Y.; Cha, S.K.; Park, K.S. Transforming growth factor β1-induced apoptosis in podocytes via the extracellular signal-regulated kinase-mammalian target of rapamycin complex 1-NADPH oxidase 4 axis. J. Biol. Chem., 2015, 290(52), 30830-30842.
280. Guo, Y.L.; Kang, B.; Yang, L.J.; Williamson, J.R. Tumor necrosis factor-α and ceramide induce cell death through different mechanisms in rat mesangial cells. Am. J. Physiol., 1999, 276(3 Pt 2), F390-F397.
281. Sheridan, A.M.; Force, T.; Yoon, H.J.; O'Leary, E.; Choukroun, G.; Taheri, M.R.; Bonventre, J.V. PLIP, a novel splice variant of Tip60, interacts with group IV cytosolic phospholipase A(2), induces apoptosis, and potentiates prostaglandin production. Mol. Cell. Biol., 2001, 21, 4470-4481.
282. Pan, Y.; Wan, J.; Liu, Y.; Yang, Q.; Liang, W.; Singhal, P.C.; Saleem, M.A.; Ding, G. sPLA2 IB induces human podocyte apoptosis via the M-type phospholipase A2 receptor. Sci. Rep., 2014, 4, 6660.
283. Muckova, K.; Duffield, J.S.; Held, K.D.; Bonventre, J.V.; Sheridan, A.M. cPLA2-interacting protein, PLIP, causes apoptosis and decreases G1 phase in mesangial cells. Am. J. Physiol. Renal Physiol., 2006, 290(1), F70-F79.
284. Miller, B.; Patel, V.A.; Sorokin, A. Cyclooxygenase-2 rescues rat mesangial cells from apoptosis induced by adriamycin via upregulation of multidrug resistance protein 1 (P-glycoprotein). J. Am. Soc. Nephrol., 2006, 17(4), 977-985.
285. Ishaque, A.; Dunn, M.J.; Sorokin, A. Cyclooxygenase-2 inhibits tumor necrosis factor α-mediated apoptosis in renal glomerular mesangial cells. J. Biol. Chem., 2003, 278(12), 10629-10640.
286. Marténez-García, C.; Izquierdo, A.; Velagapudi, V.; Vivas, Y.; Velasco, I.; Campbell, M.; Burling, K.; Cava, F.; Ros, M.; Oresic, M.; Vidal-Puig, A.; Medina-Gomez, G. Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model. Dis. Model. Mech., 2012, 5(5), 636-648.
287. Han, J.; Zhang, L.; Chen, X.; Yang, B.; Guo, N.; Fan, Y. Effects of all-trans retinoic acid on signal pathway of cyclooxygenase- 2 and Smad3 in transforming growth factor- β-stimulated glomerular mesangial cells. Exp. Biol. Med. (Maywood), 2014, 239(3), 272-283.
288. Cheng, H.; Fan, X.; Guan, Y.; Moeckel, G.W.; Zent, R.; Harris, R.C. Distinct roles for basal and induced COX-2 in podocyte injury. J. Am. Soc. Nephrol., 2009, 20(9), 1953-1962.
289. Shimamura, H.; Terada, Y.; Okado, T.; Tanaka, H.; Inoshita, S.; Sasaki, S. The PI3-kinase-Akt pathway promotes mesangial cell survival and inhibits apoptosis in vitro via NF-kappa B and Bad. J. Am. Soc. Nephrol., 2003, 14(6), 1427-1434.
290. del Nogal, M.; Luengo, A.; Olmos, G.; Lasa, M.; Rodriguez-Puyol, D.; Rodriguez-Puyol, M.; Calleros, L. Balance between apoptosis or survival induced by changes in extracellular- matrix composition in human mesangial cells: a key role for ILK-NFκB pathway. Apoptosis, 2012, 17(12), 1261-1274.
291. Zhang, H.; Sun, S.C. NF-κB in inflammation and renal diseases. Cell Biosci., 2015, 5, 63.
292. Ghosh Choudhury, G.; Zhang, J.H.; Ghosh-Choudhury, N.; Abboud, H.E. Ceramide blocks PDGF-induced DNA synthesis in mesangial cells via inhibition of Akt kinase in the absence of apoptosis. Biochem. Biophys. Res. Commun., 2001, 286(5), 1183-1190.
293. Fujikawa, K.; de Aos Scherpenseel, I.; Jain, S.K.; Presman, E.; Christensen, R.A.; Varticovski, L. Role of PI 3-kinase in angiopoietin-1-mediated migration and attachmentdependent survival of endothelial cells. Exp. Cell Res., 1999, 253(2), 663-672.
294. Sanchez-Niño, M.D.; Sanz, A.B.; Carrasco, S.; Saleem, M.A.; Mathieson, P.W.; Valdivielso, J.M.; Ruiz-Ortega, M.; Egido, J.; Ortiz, A. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol. Dial. Transplant., 2011, 26(6), 1797-1802.
295. Lee, M.H.; Choi, E.N.; Jeon, Y.J.; Jung, S.C. Possible role of transforming growth factor-β1 and vascular endothelial growth factor in Fabry disease nephropathy. Int. J. Mol. Med., 2012, 30(6), 1275-1280.
296. Kwak, D.H.; Lee, S.; Kim, S.J.; Ahn, S.H.; Song, J.H.; Choo, Y.K.; Choi, B.K.; Jung, K.Y. Ganglioside GM3 inhibits the high glucose- and TGF-β1-induced proliferation of rat glomerular mesangial cells. Life Sci., 2005, 77(20), 2540-2551.
297. Noguchi, M.; Kabayama, K.; Uemura, S.; Kang, B.W.; Saito, M.; Igarashi, Y.; Inokuchi, J. Endogenously produced ganglioside GM3 endows etoposide and doxorubicin resistance by up-regulating Bcl-2 expression in 3LL Lewis lung carcinoma cells. Glycobiology, 2006, 16(7), 641-650.
298. Tsuboi, N.; Utsunomiya, Y.; Kawamura, T.; Kawano, T.; Hosoya, T.; Ohno, T.; Yamada, H. Ganglioside as an endogenous growth suppressor for glomerular mesangial cells. Kidney Int., 2001, 60(4), 1378-1385.
299. Vukovic, I.; Bozic, J.; Markotic, A.; Ljubicic, S.; Ticinovic Kurir, T. The missing link - likely pathogenetic role of GM3 and other gangliosides in the development of diabetic nephropathy. Kidney Blood Press. Res., 2015, 40(3), 306-314.
300. Masson, E.; Wiernsperger, N.; Lagarde, M.; El Bawab, S. Glucosamine induces cell-cycle arrest and hypertrophy of mesangial cells: implication of gangliosides. Biochem. J., 2005, 388(Pt 2), 537-544.
301. New, L.A.; Martin, C.E.; Scott, R.P.; Platt, M.J.; Keyvani Chahi, A.; Stringer, C.D.; Lu, P.; Samborska, B.; Eremina, V.; Takano, T.; Simpson, J.A.; Quaggin, S.E.; Jones, N. Nephrin tyrosine phosphorylation is required to stabilize and restore podocyte foot process architecture. J. Am. Soc. Nephrol., 2016, 27(8), 2422-2435.
302. Kanda, N.; Watanabe, S. Ganglioside GQ1b enhances antidouble- stranded DNA antibody and IgG production of PBMCs from patients with systemic lupus erythematosus. J. Allergy Clin. Immunol., 2000, 105(3), 532-540.
303. Zoja, C.; Buelli, S.; Morigi, M. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatr. Nephrol., 2010, 25(11), 2231-2240.
304. Hofmann, L.P.; Ren, S.; Schwalm, S.; Pfeilschifter, J.; Huwiler, A. Sphingosine kinase 1 and 2 regulate the capacity of mesangial cells to resist apoptotic stimuli in an opposing manner. Biol. Chem., 2008, 389(11), 1399-1407.
305. Deng, Y.; Lan, T.; Huang, J.; Huang, H. Sphingosine Kinase-1/sphingosine 1-phosphate pathway in diabetic nephropathy. Chin. Med. J. (Engl.), 2014, 127(16), 3004-3010.
306. Katsuma, S.; Shiojima, S.; Hirasawa, A.; Suzuki, Y.; Takagaki, K.; Murai, M.; Kaminishi, Y.; Hada, Y.; Koba, M.; Muso, E.; Miyawaki, S.; Ohgi, T.; Yano, J.; Tsujimoto, G. Genomic analysis of a mouse model of immunoglobulin A nephropathy reveals an enhanced PDGF-EDG5 cascade. Pharmacogenomics J., 2001, 1(3), 211-217.
307. Katsuma, S.; Hada, Y.; Ueda, T.; Shiojima, S.; Hirasawa, A.; Tanoue, A.; Takagaki, K.; Ohgi, T.; Yano, J.; Tsujimoto, G. Signalling mechanisms in sphingosine 1- phosphate-promoted mesangial cell proliferation. Genes Cells, 2002, 7(12), 1217-1230.
308. Huwiler, A.; Bourquin, F.; Kotelevets, N.; Pastukhov, O.; Capitani, G.; Grütter, M.G.; Zangemeister-Wittke, U. A prokaryotic S1P lyase degrades extracellular S1P in vitro and in vivo: implication for treating hyperproliferative disorders. PLoS One, 2011, 6(8), e22436.
309. Jiang, J.; Huang, X.; Wang, Y.; Deng, A.; Zhou, J. FTY720 induces cell cycle arrest and apoptosis of rat glomerular mesangial cells. Mol. Biol. Rep., 2012, 39(8), 8243-8250.
310. Xin, C.; Ren, S.; Eberhardt, W.; Pfeilschifter, J.; Huwiler, A. FTY720 suppresses interleukin-1β-induced secretory phospholipase A2 expression in renal mesangial cells by a transcriptional mechanism. Br. J. Pharmacol., 2007, 150(7), 943-950.
311. Xin, C.; Ren, S.; Kleuser, B.; Shabahang, S.; Eberhardt, W.; Radeke, H.; Schäfer-Korting, M.; Pfeilschifter, J.; Huwiler, A. Sphingosine 1-phosphate cross-activates the Smad signaling cascade and mimics transforming growth factor-β- induced cell responses. J. Biol. Chem., 2004, 279(34), 35255-35262.
312. Galvani, S.; Sanson, M.; Blaho, V.A.; Swendeman, S.L.; Obinata, H.; Conger, H.; Dahlbäck, B.; Kono, M.; Proia, R.L.; Smith, J.D.; Hla, T. HDL-bound sphingosine 1- phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation. Sci. Signal., 2015, 8(389), ra79.
313. Liu, Y. Cellular and molecular mechanisms of renal fibrosis. Nat. Rev. Nephrol., 2011, 7(12), 684-696.
314. Ren, S.; Babelova, A.; Moreth, K.; Xin, C.; Eberhardt, W.; Doller, A.; Pavenstädt, H.; Schaefer, L.; Pfeilschifter, J.; Huwiler, A. Transforming growth factor-β2 upregulates sphingosine kinase-1 activity, which in turn attenuates the fibrotic response to TGF-β2 by impeding CTGF expression. Kidney Int., 2009, 76(8), 857-867.
315. Long, D.A.; Price, K.L. Sphingosine kinase-1: a potential mediator of renal fibrosis. Kidney Int., 2009, 76(8), 815-817.
316. Katsuma, S.; Ruike, Y.; Yano, T.; Kimura, M.; Hirasawa, A.; Tsujimoto, G. Transcriptional regulation of connective tissue growth factor by sphingosine 1-phosphate in rat cultured mesangial cells. FEBS Lett., 2005, 579(12), 2576-2582.
317. Wünsche, C.; Koch, A.; Goldschmeding, R.; Schwalm, S.; Meyer Zu Heringdorf, D.; Huwiler, A.; Pfeilschifter, J. Transforming growth factor β2 (TGF-β2)-induced connective tissue growth factor (CTGF) expression requires sphingosine 1-phosphate receptor 5 (S1P5) in human mesangial cells. Biochim. Biophys. Acta., 2015, 1851, 519-526.
318. Huang, K.; Liu, W.; Lan, T.; Xie, X.; Peng, J.; Huang, J.; Wang, S.; Shen, X.; Liu, P.; Huang, H. Berberine reduces fibronectin expression by suppressing the S1P-S1P2 receptor pathway in experimental diabetic nephropathy models. PLoS One, 2012, 7(8), e43874.
319. Liu, W.; Lan, T.; Xie, X.; Huang, K.; Peng, J.; Huang, J.; Shen, X.; Liu, P.; Huang, H. S1P2 receptor mediates sphingosine- 1-phosphate-induced fibronectin expression via MAPK signaling pathway in mesangial cells under high glucose condition. Exp. Cell Res., 2012, 318(8), 936-943.
320. Huang, K.; Huang, J.; Chen, C.; Hao, J.; Wang, S.; Huang, J.; Liu, P.; Huang, H. AP-1 regulates sphingosine kinase 1 expression in a positive feedback manner in glomerular mesangial cells exposed to high glucose. Cell. Signal., 2014, 26(3), 629-638.
321. Chen, C.; Huang, K.; Hao, J.; Huang, J.; Yang, Z.; Xiong, F.; Liu, P.; Huang, H. Polydatin attenuates AGEs-induced upregulation of fibronectin and ICAM-1 in rat glomerular mesangial cells and db/db diabetic mice kidneys by inhibiting the activation of the SphK1-S1P signaling pathway. Mol. Cell. Endocrinol., 2016, 427, 45-56.
322. Yang, Z.; Xiong, F.; Wang, Y.; Gong, W.; Huang, J.; Chen, C.; Liu, P.; Huang, H. TGR5 activation suppressed S1P/S1P2 signaling and resisted high glucose-induced fibrosis in glomerular mesangial cells. Pharmacol. Res., 2016, 111, 226-236.
323. Koch, A.; Völzke, A.; Wünsche, C.; Meyer zu Heringdorf, D.; Huwiler, A.; Pfeilschifter, J. Thiazolidinedionedependent activation of sphingosine kinase 1 causes an antifibrotic effect in renal mesangial cells. Br. J. Pharmacol., 2012, 166(3), 1018-1032.
324. Martini, S.; Krämer, S.; Loof, T.; Wang-Rosenke, Y.; Daig, U.; Budde, K.; Neumayer, H.H.; Peters, H. S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis. Am. J. Physiol. Renal Physiol., 2007, 292(6), F1761-F1770.
325. Balwani, M.; Burrow, T.A.; Charrow, J.; Goker-Alpan, O.; Kaplan, P.; Kishnani, P.S.; Mistry, P.; Ruskin, J.; Weinreb, N. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. Mol. Genet. Metab., 2016, 117(2), 95-103.
326. Abe, A.; Gregory, S.; Lee, L.; Killen, P.D.; Brady, R.O.; Kulkarni, A.; Shayman, J.A. Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J. Clin. Invest., 2000, 105(11), 1563-1571.
327. Ashe, K.M.; Budman, E.; Bangari, D.S.; Siegel, C.S.; Nietupski, J.B.; Wang, B.; Desnick, R.J.; Scheule, R.K.; Leonard, J.P.; Cheng, S.H.; Marshall, J. Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease. Mol. Med., 2015, 21, 389-399.
328. Girard, M.C.; Sacerdoti, F.; Rivera, F.P.; Repetto, H.A.; Ibarra, C.; Amaral, M.M. Prevention of renal damage caused by Shiga toxin type 2: Action of Miglustat on human endothelial and epithelial cells. Toxicon, 2015, 105, 27-33.
329. Boini, K.M.; Zhang, C.; Xia, M.; Han, W.Q.; Brimson, C.; Poklis, J.L.; Li, P.L. Visfatin-induced lipid raft redox signaling platforms and dysfunction in glomerular endothelial cells. Biochim. Biophys. Acta., 2010, 1801, 1294-1304.
330. Morrissey, J.J. Pleiotropic effects of amitriptyline ameliorate renal fibrosis. Kidney Int., 2009, 75(6), 583-584.
331. Yi, F.; Zhang, A.Y.; Li, N.; Muh, R.W.; Fillet, M.; Renert, A.F.; Li, P.L. Inhibition of ceramide-redox signaling pathway blocks glomerular injury in hyperhomocysteinemic rats. Kidney Int., 2006, 70(1), 88-96.
332. Jo, S.K.; Bajwa, A.; Awad, A.S.; Lynch, K.R.; Okusa, M.D. Sphingosine-1-phosphate receptors: biology and therapeutic potential in kidney disease. Kidney Int., 2008, 73(11), 1220-1230.
333. Sui, M.; Zhou, J.; Xie, R.; Liu, X.; Mu, S.; Jia, X.; Ma, J.; Wu, H. The sphingosine-1-phosphate receptor agonist FTY720 prevents the development of anti-glomerular basement membrane glomerulonephritis. Mol. Biol. Rep., 2012, 39(1), 389-397.
334. Krämer, S.; Binder, E.; Loof, T.; Wang-Rosenke, Y.; Martini, S.; Khadzhynov, D.; Budde, K.; Neumayer, H.H.; Peters, H. The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy. Am. J. Physiol. Renal Physiol., 2009, 297(1), F218-F227.
335. Fujishiro, J.; Suzuki, C.; Kudou, S.; Yasue, T.; Hakamata, Y.; Takahashi, M.; Murakami, T.; Hashizume, K.; Kobayashi, E. Change from cyclosporine to combination therapy of mycophenolic acid with the new sphingosine-1-phosphate receptor agonist, KRP-203, prevents host nephrotoxicity and transplant vasculopathy in rats. J. Heart Lung Transplant., 2006, 25(7), 825-833.
336. Tedesco-Silva, H.; Szakaly, P.; Shoker, A.; Sommerer, C.; Yoshimura, N.; Schena, F.P.; Cremer, M.; Hmissi, A.; Mayer, H.; Lang, P. FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double- blind study. Transplantation, 2007, 84(7), 885-892.
337. Förster, A.; Emmler, T.; Schwalm, S.; Ebadi, M.; Heringdorf, D.M.; Nieuwenhuis, B.; Kleuser, B.; Huwiler, A.; Pfeilschifter, J. Glucocorticoids protect renal mesangial cells from apoptosis by increasing cellular sphingosine-1- phosphate. Kidney Int., 2010, 77(10), 870-879.